6 completed, 3 terminated. 9 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Terminated 3 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Placebo - Cap: new trials by email Literature Review of Placebo - Cap trials Research Report on Placebo - Cap
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabergoline for the Treatment of Chronic Pain Due to Endometriosis Cabergoline 0.5 MG, Placebo - Cap - Endometriosis | Phase 2 | Completed | Boston Children's Hospital | 129 | 2019-12-02 | 2026-01-28 |
| ENAC Blockade and Arterial Stiffness Placebo - Cap, Amiloride Pill - Overweight and Obesity, Insulin Resistance | Phase 2 / Phase 3 | Completed | University of Missouri-Columbia | 137 | 2019-07-15 | 2025-12-30 |
| Fexofenadine Use in Gastroesophageal Reflux Symptoms Fexofenadine, Placebo - Cap - Gastroesophageal Reflux | Phase 2 | Terminated | Stanford University | 11 | 2018-02-07 | 2021-02-17 |
| INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Mifepristone, Placebo - Cap - Alcohol Use Disorder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 65 | 2017-09-26 | 2025-05-30 |
| OPTIMA-TBI Pilot Study Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules., Placebo - Cap - Mild Traumatic Brain Injury | Phase 2 | Terminated | University of Michigan | 44 | 2017-09-12 | 2023-05-23 |
| A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia SEP-363856, Placebo - Cap - Schizophrenia | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 245 | 2016-12-05 | 2024-07-05 |
| Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer escitalopram, Moclobemide, Placebo - Cap - Addiction | Phase 2 | Terminated | China Medical University Hospital | 90 | 2016-01-14 | 2019-07-24 |
| NMDA Modulation in Major Depressive Disorder in Late- Life NMDA, Sertraline, Placebo - Cap - Depressive Disorder, Major | Phase 2 | Completed | Chang Gung Memorial Hospital | 136 | 2016-01-01 | 2020-12-01 |
| Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function Anastrozole 1mg, Clomiphene Citrate 25mg, Placebo - Cap - Hypogonadism, Male | Phase 2 | Completed | Albany Medical College | 24 | 2015-04-02 | 2019-11-18 |
Alcoholism (1) · Behavior, Addictive (1) · Brain Concussion (1) · Depressive Disorder, Major (1) · Endometriosis (1) · Eunuchism (1) · Gastroesophageal Reflux (1) · Insulin Resistance (1) · Obesity (1) · Overweight (1) · Schizophrenia (1)
Albany Medical College (1) · Boston Children's Hospital (1) · Chang Gung Memorial Hospital (1) · China Medical University Hospital (1) · Johns Hopkins University (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Stanford University (1) · University of Michigan (1) · University of Missouri-Columbia (1)
United States (6) · Hungary (1) · Romania (1) · Russia (1) · Taiwan (1) · Ukraine (1)
Camila Manrique Acevedo, MD (1) · Frederick Korley, M.D., Ph.D. (1) · Ko Ying-Chin, PHD (1) · Mary E McCaul, PhD (1) · Robert C Welliver, MD (1)
PMID 32294346, PMID 35023557, PMID 36369028
2016 (1), U01AA020890 (1)